Trials / Completed
CompletedNCT04150289
A Disease Registry Encompassing the Care Of Patients With Multiple Myeloma on Panobinostat
A Disease Registry Encompassing the Care of Patients With Multiple Myeloma on Panobinostat (RECOMM)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 248 (actual)
- Sponsor
- pharmaand GmbH · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to describe current treatment patterns in the real-world setting among patients with multiple myeloma who are initiating treatment with (or changing treatment to) panobinostat and explore the associations with baseline patient characteristics, healthcare resource utilization, and clinical outcomes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Farydak | non-interventional study |
Timeline
- Start date
- 2019-11-04
- Primary completion
- 2022-03-30
- Completion
- 2022-03-30
- First posted
- 2019-11-04
- Last updated
- 2023-06-15
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT04150289. Inclusion in this directory is not an endorsement.